277 related articles for article (PubMed ID: 28294551)
1. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Cavallari LH; Beitelshees AL; Blake KV; Dressler LG; Duarte JD; Elsey A; Eichmeyer JN; Empey PE; Franciosi JP; Hicks JK; Holmes AM; Jeng L; Lee CR; Lima JJ; Limdi NA; Modlin J; Obeng AO; Petry N; Pratt VM; Skaar TC; Tuteja S; Voora D; Wagner M; Weitzel KW; Wilke RA; Peterson JF; Johnson JA
Clin Transl Sci; 2017 May; 10(3):143-146. PubMed ID: 28294551
[No Abstract] [Full Text] [Related]
2. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
Hachad H; Ramsey LB; Scott SA
Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
[No Abstract] [Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
[TBL] [Abstract][Full Text] [Related]
4. What to expect from the Pharmacogenomics Research Network.
Long RM; Berg JM
Clin Pharmacol Ther; 2011 Mar; 89(3):339-41. PubMed ID: 21326260
[No Abstract] [Full Text] [Related]
5. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.
Tan-Koi WC; Lim ES; Teo YY
Pharmacogenomics J; 2017 Mar; 17(2):121-127. PubMed ID: 26902540
[TBL] [Abstract][Full Text] [Related]
6. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE
Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517
[No Abstract] [Full Text] [Related]
7. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Dunnenberger HM; Crews KR; Hoffman JM; Caudle KE; Broeckel U; Howard SC; Hunkler RJ; Klein TE; Evans WE; Relling MV
Annu Rev Pharmacol Toxicol; 2015; 55():89-106. PubMed ID: 25292429
[TBL] [Abstract][Full Text] [Related]
8. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
Pirmohamed M; Aithal GP; Behr E; Daly A; Roden D
Clin Pharmacol Ther; 2011 Jun; 89(6):784-5. PubMed ID: 21593754
[TBL] [Abstract][Full Text] [Related]
9. The National Institutes of Health Blueprint for Neuroscience Research.
Baughman RW; Farkas R; Guzman M; Huerta MF
J Neurosci; 2006 Oct; 26(41):10329-31. PubMed ID: 17035514
[No Abstract] [Full Text] [Related]
10. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
Lee YM; Danahey K; Knoebel RW; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):23-30. PubMed ID: 30531378
[TBL] [Abstract][Full Text] [Related]
11. The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge.
Hodge AE; Altman RB; Klein TE
Clin Pharmacol Ther; 2007 Jan; 81(1):21-4. PubMed ID: 17185992
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic associations and evidence-based pharmacogenomics guidelines: supporting label and off-label use of drug-gene interaction data.
Kisor DF; Monte AA; Müller DJ
Pharmacogenomics; 2020 May; 21(7):427-430. PubMed ID: 32319356
[No Abstract] [Full Text] [Related]
13. Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.
Sissung TM; McKeeby JW; Patel J; Lertora JJ; Kumar P; Flegel WA; Adams SD; Eckes EJ; Mickey F; Plona TM; Mellot SD; Baugher RN; Wu X; Soppet DR; Barcus ME; Datta V; Pike KM; DiPatrizio G; Figg WD; Goldspiel BR
J Clin Pharmacol; 2017 Oct; 57 Suppl 10(Suppl 10):S67-S77. PubMed ID: 28921647
[TBL] [Abstract][Full Text] [Related]
14. Attitudes of clinicians following large-scale pharmacogenomics implementation.
Peterson JF; Field JR; Shi Y; Schildcrout JS; Denny JC; McGregor TL; Van Driest SL; Pulley JM; Lubin IM; Laposata M; Roden DM; Clayton EW
Pharmacogenomics J; 2016 Aug; 16(4):393-8. PubMed ID: 26261062
[TBL] [Abstract][Full Text] [Related]
15. Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH Pharmacogenetics Research Network.
Long RM
Clin Pharmacol Ther; 2007 Mar; 81(3):450-4. PubMed ID: 17339874
[TBL] [Abstract][Full Text] [Related]
16. John Niederhuber: thinking like a director.
Vanchieri C
J Natl Cancer Inst; 2006 Sep; 98(18):1266-8. PubMed ID: 16985241
[No Abstract] [Full Text] [Related]
17. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Avoiding Benzopyrone Hepatotoxicity in Lymphedema Management-The Role of Pharmacogenetics, Metabolic Enzyme Gene Identification, and Patient Selection.
Hu M; Piller NB
Lymphat Res Biol; 2017 Dec; 15(4):317-323. PubMed ID: 29087786
[TBL] [Abstract][Full Text] [Related]
19. The role of cooperative groups in cancer clinical trials.
Mauer AM; Rich ES; Schilsky RL
Cancer Treat Res; 2007; 132():111-29. PubMed ID: 17305018
[No Abstract] [Full Text] [Related]
20. Impact of the National Institutes of Health Consensus Development Program on stimulating National Institutes of Health-funded research, 1998 to 2001.
Portnoy B; Miller J; Brown-Huamani K; DeVoto E
Int J Technol Assess Health Care; 2007; 23(3):343-8. PubMed ID: 17579937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
